What is it about?
A mouse biomarker model provides key insights into cellular mediators of immunotherapy response that are present in the tumor microenvironment prior to treatment. The results shown here serve as a foundation for future clinical studies testing the combination of losartan with immune checkpoint blockade in glioblastoma patients.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Improving immunotherapy outcomes for the majority of glioblastoma patients remains a critically unmet need. In mouse models of glioblastoma, the use of a safe, affordable, and widely prescribed antihypertensive agent (losartan) overcomes immune-related adverse events, enhances antitumor immune activity, and improves survival outcomes of immune checkpoint blocker therapy.
Read the Original
This page is a summary of: Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models, Proceedings of the National Academy of Sciences, February 2023, Proceedings of the National Academy of Sciences,
DOI: 10.1073/pnas.2219199120.
You can read the full text:
Contributors
The following have contributed to this page
